Patient Engagement Synapse
  • Join now
  • Login
COVID-19 hub
  • Home
  • People
  • Organizations
  • Initiatives
  • Events
  • Resources
  • Conditions
  • Trainings
  • Patient Pledge
    • Take the Pledge
    • The Pledge Record
  • Reports
  • Join now
  • Login

BioMarin

Pharmaceutical Company
Join organization
  • Info
  • People 2
  • Initiatives 2
  • Events 0
  • Resources 0

About the organization

Read more

At BioMarin, we focus on developing first-in-class and best-in-class therapeutics that provide meaningful advances to patients who live with serious and life-threatening rare genetic diseases. BioMarin remains steadfast to its original mission—to bring new treatments to market that will make a big impact on small patient populations. These patient populations are mostly children, suffering from diseases so rare, that the entire patient population can number as few as 1,000 people worldwide. These conditions are often inherited, difficult to diagnose, progressively debilitating, have few, if any, treatment options, and are usually ignored.Please see - http://www.biomarin.com/

Mission : At BioMarin, we focus on developing first-in-class and best-in-class therapeutics that provide meaningful advances to patients who live with serious and life-threatening rare genetic diseases. BioMarin remains steadfast to its original mission—to bring new treatments to market that will make a big impact on small patient populations. These patient populations are mostly children, suffering from diseases so rare, that the entire patient population can number as few as 1,000 people worldwide. These conditions are often inherited, difficult to diagnose, progressively debilitating, have few, if any, treatment options, and are usually ignored.

Vision : Please see - http://www.biomarin.com/

Badges earned

Website

http://www.biomarin.com/

People

MM

Maria Meehan

BioMarin

PH

Paul Humphrey

Associate Director Patient Advocacy - BioMarin

London, United Kingdom

BioMarin

Initiatives

  Patient engagement in the selection and development of clinical outcome assessments (COA)

Evidera, Boehringer Ingelheim, PFMD ,
+ 12

Global

Completed less than one year ago

  Patient engagement in the regulatory submission phase

BioMarin, Janssen - Johnson & Johnson, PFMD ,
LP
+ 13

Global

Completed less than one year ago

Do you need help?

  • Contact us
  • Help Center
  • Latest updates
  • Cookie privacy options

Useful links

  • About us
  • Features
  • Search tool
  • Terms and Conditions
  • Privacy Policy
  • Geographical
  • Medical scope
  • Timeline
  • Patient matrix
  • Medicine lifecycle

Join our newsletter

Get the latest information on Patient Focused Medicines Development and stay connected with our activities.

5.0.1@staging
© Copyright SYNAPSE 2021. All Rights Reserved Powered by The Synergist.